Home › Research › Cognitive tests and assessment
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
AD2000 Collaborative Group, Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J.. The Lancet. Neurology, 2008-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Cardiovascular risk factors and a history of vascular disease can increase the risk of Alzheimer's disease (AD). AD is less common in aspirin users than non-users, and there are plausible biological mechanisms whereby aspirin might slow the progression of either vascular or Alzheimer-type pathology. We assessed the benefits of aspirin in patients with AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
AD2000 Collaborative Group, Bentham, P., Gray, R., Sellwood, E., Hills, R., Crome, P., et al. (2008). Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(07)70293-4
Vancouver
AD2000 Collaborative Group, Bentham P, Gray R, Sellwood E, Hills R, Crome P, et al. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. The Lancet. Neurology. 2008. doi:10.1016/s1474-4422(07)70293-4. PMID: 18068522.
BibTeX
@article{study2008-18068522,
author = {{AD2000 Collaborative Group} and Bentham, P. and Gray, R. and Sellwood, E. and Hills, R. and Crome, P. and Raftery, J.},
title = {{Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial}},
journal = {The Lancet. Neurology},
year = {2008},
doi = {10.1016/s1474-4422(07)70293-4},
pmid = {18068522},
url = {https://doi.org/10.1016/s1474-4422(07)70293-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- AD is less common in aspirin users than non-users, and there are plausible biological mechanisms whereby aspirin might slow the progression of either vascular or Alzheimer-type pathology.
- We assessed the benefits of aspirin in patients with AD.
- Methods 310 community-resident patients who had AD and who had no potential indication or definite contraindication for aspirin were randomly assigned to receive open-label aspirin (n=156; one 75-mg enteric-coated tablet per day, to continue indefinitely) or to avoid aspirin (n=154).
- Primary outcome measures were cognition (assessed with the mini-mental state examination [MMSE]) and functional ability (assessed with the Bristol activities of daily living scale [BADLS]).
Why it matters
This randomised trial assessed whether aspirin slows progression in people with Alzheimer's disease, based on the observation that Alzheimer's disease is less common in aspirin users. It tested aspirin as a possible treatment, not a cure or prevention.
Study details
- Study designrandomized controlled trial
- Participants156
- Evidence strengthHigh
How this study scored 65/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 60 of the 93 points we could judge it on, which is 65 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 156 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 147 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.3 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 3 / 6 | Cited 6.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author AD Collaborative Group holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18068522) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 60 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 60 of the 93 points we could judge it on is 65 out of 100. |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.